Alembic gets USFDA nod for Nitrofurantoin Capsules USP

Alembic has a cumulative total of 146 ANDA approvals (128 final approvals and 18 tentative approvals) from USFDA.

40
USFDA
Picture: Pixabay

Last Updated on July 3, 2021 by The Health Master

Alembic Pharmaceuticals announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nitrofurantoin Capsules, USP (Macrocrystals), 25 mg, 50 mg and 100 mg.

Medicine Capsule
Picture: Pixabay

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Macrodantin Capsules, 25 mg, 50 mg, and 100 mg, of Alvogen Malta Operations. Nitrofurantoin capsules, USP (Macrocrystals) is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species.

Nitrofurantoin Capsules, USP (Macrocrystals), 25 mg, 50 mg and 100 mg have an estimated market size of $ 23 million for twelve months ending March 2021 according to IQVIA.

Alembic has a cumulative total of 146 ANDA approvals (128 final approvals and 18 tentative approvals) from USFDA.

Axio Biosolution gets USFDA nod for Patch for bleeding control

Glenmark gets USFDA nod for generic Lung cancer drug

USFDA okays Tocilizumab for treatment of Covid-19

Zydus Cadila gets tentative nod from USFDA for Pemetrexed for Injection

Cipla gets USFDA nod for Inhalation product

Zydus Cadila gets tentative nod from USFDA for Fingolimod Capsules

NPPA fixes retail prices of 3 formulations

DCGI allows Cipla to import Moderna vaccine in India

First ‘Skin Bank’ set up: Hetero and Rotary Club provide financial…

Axio Biosolution gets USFDA nod for Patch for bleeding control

NITI Aayog releases report on not-for-profit hospital model in India

Govt to start two more Vaccine Testing Laboratories

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner